NEXTOM

Abstract:

The NEXTOM project aims to develop innovative antibody-drug conjugates (ADCs) targeting components of the tumour microenvironment (such as FAP, Endoglin and Endo180), to treat invasive solid tumours with greater efficacy and lower toxicity.

The initiative includes the selection of therapeutic candidates, their validation in advanced preclinical models, including animals with a humanised immune system, and the study of their stability, pharmacokinetics, and toxicological profile. The manufacturing process and a pilot batch will also be developed to enable progress toward the clinical phase.

Leitat’s role in the project:

The project is led by Oncomatryx, with the collaboration of Leitat, which contributes its expertise in preclinical models, ADME, and bioanalysis.

NEXTOM seeks to expand the therapeutic arsenal available in oncology, strengthening innovation in stroma-targeted therapies and supporting the transition toward personalised medicine.